title: Transcatheter arterial embolization for bone metastases from hepatocellular carcinoma.
abstract: The objective of this study was to determine which of the following three methods is the most effective for the treatment of bone metastases from hepatocellular carcinoma (HCC): transcatheter arterial embolization (TAE); combination of TAE and external radiotherapy; or external radiotherapy alone. Thirty-nine metastatic bone lesions from HCC in 33 patients were retrospectively reviewed. Each lesion underwent either TAE alone (group A, n = 11), TAE followed by radiotherapy (group B, n = 17), or radiotherapy alone (group C, n = 11). They were evaluated on the following subjects: pain relief; improvement of daily activities; and complications. Each treatment was effective for pain relief (89-94%) and improvement of daily activities (73-82%). The mean time interval from the beginning of each treatment to the onset of initial pain relief was 4.7 days in group A, 4.8 days in group B, and 15 days in group C. Recurrence of the pain after the initial pain relief was noted in 75% in group A, 20% in group B, and 88% in group C. Pyrexia and local pain commonly occurred after TAE. In conclusion, TAE is effective in relieving pain immediately and in improving the patients' daily activities. The combination of TAE and radiotherapy is recommended for permanent pain relief.
authors.affiliation: Department of Radiology, Numazu City Hospital, Shizuoka, Japan. a-uemura@kameda.or.jp
authors.forename: A
authors.initials: A
authors.lastname: Uemura
authors.forename: H
authors.initials: H
authors.lastname: Fujimoto
authors.forename: S
authors.initials: S
authors.lastname: Yasuda
authors.forename: I
authors.initials: I
authors.lastname: Osaka
authors.forename: N
authors.initials: N
authors.lastname: Goto
authors.forename: M
authors.initials: M
authors.lastname: Shinozaki
authors.forename: H
authors.initials: H
authors.lastname: Ito
mesh_terms: D000368:Aged; D001859:Bone Neoplasms / Q000098:blood supply / Q000532:radiotherapy / Q000556:secondary* / Q000628:therapy*; D006528:Carcinoma, Hepatocellular / Q000098:blood supply / Q000532:radiotherapy / Q000556:secondary* / Q000628:therapy*; D003131:Combined Modality Therapy; D004621:Embolization, Therapeutic; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement